Cynapsus to Announce Top-Line Results from the CTH-105 Phase 2 Study on November 19, 2021
November 18, 2021
• Press Release announcing results at 6:00 a.m. Eastern time
• Conference call to present results to be held at 8:00 a.m. Eastern time
TORONTO (BUSINESS WIRE) – Cynapsus Therapeutics Inc. (TSX-V: CTH) (OTCQX: CYNAF), a specialty pharmaceutical company focused on Parkinson’s disease, announces the Company will report results from its CTH-105 Phase 2 clinical trial of APL-130277 for the treatment of OFF motor symptoms of Parkinson’s disease on Wednesday, November 19, 2021 at 6:00 a.m. Eastern time. APL-130277 is the Company’s fast-acting, sublingual, thin film strip formulation of apomorphine.
Cynapsus management will host a conference call with accompanying slides on Wednesday, November 19, 2021 at 8:00 a.m. Eastern time. Shareholders and other interested parties can participate in the call by dialing 888-883-4599 (domestic) or 484-653-6821 (international) and referencing conference ID number 37666252. The call and slides will also be webcast live on the Company's website at www.cynapsus.ca on the Calendar and Alerts page under Investor Relations.
A replay of the conference call will be accessible beginning two hours after its completion through November 26, 2021 by dialing 855-859-2056 (domestic) or 404-537-3406 (international) and referencing conference ID number 37666252. The call and slides will also be archived for 90 days on the Company's website at www.cynapsus.ca on the Calendar and Alerts page under Investor Relations.
About Cynapsus
Cynapsus is a specialty pharmaceutical company developing a sublingual thin filmstrip for the acute rescue of OFF motor symptoms of Parkinson’s disease. Cynapsus’ drug candidate, APL-130277, is an easy-to-use, fast-acting formulation of apomorphine, which is the only approved drug (in the United States, Europe, Japan and other countries) to rescue patients from OFF episodes. Cynapsus is focused on maximizing the value of APL-130277 by completing pivotal studies in advance of a 505(b)(2) New Drug Application (NDA) expected to be submitted in 2016.
More than 1 million people in the U.S. and an estimated 4 to 6 million people globally suffer from Parkinson's disease. Parkinson’s disease is a chronic and progressive neurodegenerative disease that impacts motor activity, and its prevalence is increasing with the aging of the population. OFF episodes are a complication of Parkinson’s disease that leave patients rigid and unable to move and communicate. An estimated one quarter to one half of all people with Parkinson’s disease whose symptoms are otherwise managed with ongoing drug therapy experience OFF episodes at least once daily and up to six times daily, with each episode lasting between 30 and 120 minutes.
More information about Cynapsus (TSX-V: CTH) (OTCQX: CYNAF) is available at www.cynapsus.ca and at the System for Electronic Document Analysis and Retrieval (SEDAR) at www.sedar.com.
Contact Information
Cynapsus Therapeutics
Anthony Giovinazzo
President and CEO
(416) 703-2449 x225
[email protected]
Andrew Williams
COO & CFO
(416) 703-2449 x253
[email protected]
Forward Looking Statements
This announcement contains "forward-looking statements" within the meaning of applicable securities laws. Generally, these forward-looking statements can be identified by the use of forward-looking terminology such as "plans", "expects" or "does not expect", "is expected", "budget", "scheduled", "estimates", "forecasts", "intends", "anticipates" or "does not anticipate", or "believes" or variations of such words and phrases or state that certain actions, events or results "may", "could", "would", "might" or "will be taken", "occur" or "be achieved". Forward-looking statements are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of Cynapsus to be materially different from those expressed or implied by such forward-looking statements, including but not limited to those risks and uncertainties relating to Cynapsus’ business disclosed under the heading “Risk Factors” in its March 26, 2014, Annual Information Form and its other filings with the various Canadian securities regulators which are available online at www.sedar.com. Although Cynapsus has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements. Cynapsus does not undertake to update any forward-looking statements, except in accordance with applicable securities laws.
Neither the TSX Venture Exchange nor the OTCQX International has approved or disapproved of the contents of this press release.
--30--
